(Q40171094)

18 September 2017

title

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older (English)

1 reference

18 September 2017

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Nezam Afdhal

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

11

Kris Kowdley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Sammy Saab

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sarah H Park

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Masashi Mizokami

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Masao Omata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ed Eggleton

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Yanni Zhu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Steven J Knox

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Phil Pang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mani Subramanian

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

24 December 2015

1 reference

18 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

1112-1119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26704693%20AND%20SRC:MED&resulttype=core&format=json

The impact of hepatitis C burden: an evidence-based approach.

10 June 2020

cites work

1 reference

7 January 2021

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

1 reference

7 January 2021

Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

1 reference

7 January 2021

The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010.

1 reference

7 January 2021

Projecting future complications of chronic hepatitis C in the United States

1 reference

7 January 2021

Global burden of disease (GBD) for hepatitis C.

1 reference

7 January 2021

Global burden of hepatitis C: considerations for healthcare providers in the United States

1 reference

7 January 2021

Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention

1 reference

7 January 2021

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

7 January 2021

Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma

1 reference

7 January 2021

Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review.

1 reference

7 January 2021

Changing trends in hepatitis C infection over the past 50 years in Japan

1 reference

7 January 2021

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

7 January 2021

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

7 January 2021

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

1 reference

7 January 2021

Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.

1 reference

7 January 2021

Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.

1 reference

7 January 2021

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

1 reference

7 January 2021

Factors contributing to ribavirin-induced anemia

1 reference

7 January 2021

1 reference

7 January 2021

Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.

1 reference

7 January 2021

Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels

1 reference

7 January 2021

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

1 reference

7 January 2021

Hepatitis C Infection in the Elderly

1 reference

7 January 2021

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

1 reference

7 January 2021

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

1 reference

7 January 2021

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

1 reference

7 January 2021

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

7 January 2021

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

7 January 2021

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

7 January 2021

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

1 reference

7 January 2021

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

1 reference

7 January 2021

Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir

1 reference

7 January 2021